Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

John Koreth, Maria Carmen Martinez Munoz, Jeremy Pantin, Shukaib Arslan, Jaime Sanz, Alison Loren, Benedetta Rambaldi, Elisa Sala, Avichai Shimoni, Tsila Zuckerman, Corey Cutler, Lisette Acevedo, Kham Phenis, Eugene Sun, Stephen Connelly, Joel Rothman

Blood (2025) 146 (Supplement 1): 274.

https://doi.org/10.1182/blood-2025-274

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Jose Miguel Mateos Perez, Francesc Fernández-Avilés, Maria Teresa Cibeira López, Maria Carmen Martinez Munoz, Carlos Fernandez de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Maria Suarez-Lledo, Maria Queralt Salas Gay, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Montserrat Rovira, Joan Batista Blade Creixenti, Laura Rosiñol Dachs

Blood (2025) 146 (Supplement 1): 5776.

https://doi.org/10.1182/blood-2025-5776

Published: 2025

Journal Articles

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Blood (2025) 146 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2025-3621

Published: 2025

Journal Articles

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2025-3620

Published: 2025

Journal Articles

Usefulness of C5b9 deposition analysis for the diagnosis, treatment, and monitoring of patients with transplant-associated thrombotic microangiopathy

Julia Martinez-Sanchez, Candela Ceballos, Nerea Arratibel, Itziar Oiartzabal Ormategi, Hodei Arrizabalaga Fernández, Lourdes Aguirre, Maria Suarez-Lledo, Ana Belén Moreno-Castaño, Miquel Blasco, Marta Palomo, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira, Enric Carreras, Mª Queralt Salas, Maribel Diaz-Ricart

Blood (2025) 146 (Supplement 1): 4210.

https://doi.org/10.1182/blood-2025-4210

Published: 2025

Journal Articles

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raul Cordoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez, Blanca Sánchez-González, Miriam Moreno, Norma Gutiérrez, David Alonso Castronuño, Jimena Cannata, Pilar Gomez Prieto, Laurentino Benito, Tamara Torrado, Joan Buch, Juan Carlos Caballero, Nazaret Dominguez, Raquel Santiago Alonso, Isabel González-gascón-y-Marín, Maria Moya Arnao, Beatriz De La Cruz, Cecilia Carpio, Maria Dolores Gutiérrez-Meca Maestre, Luis Antonio López Gómez, Eukene Gainza, Maria Rocio Figueroa Mora, Paula Fernandez-Caldas, Mariana Bastos-Oreiro, Paola Villafuerte Gutiérrez, Samuel Romero Dominguez, Belen Navarro Matilla, Izaskun Zeberio, Emilia Pardal De La Mano, Antonio Gutierrez, Eva Donato, Javier Nuñez, Teresa Cobo, Begona Mendibil, Inigo Olazabal Eizaguirre, Maria Isabel Gomez Roncero, Cristina Barrenetxea, Haridian de la Nuez, Sara Ferrero, Roberto Trelles, Maria Garcia Roa, Luis Ignacio Sancho Val, Sofia Martin-Consuegra, Maria Luisa Bengochea, Carmen Alonso Prieto, Elena Ramila, Hugo Daniel Luzardo Henríquez, Maria Jesus Peñarrubia, Alfonso Ortiz, Ignacio Mahillo, Eva Domingo Domenech

Blood (2025) 146 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2025-6264

Published: 2025

Journal Articles

Monocytosis as prognostic factor for chronic graft versus host disease

Cristina Marrero-Cepeda, Teresa Caballero-Velazquez, Francisco Manuel Martin-Dominguez, Nancy Rodriguez-Torres, Cristina Blazquez Go I, Maria Carmen Martinez Munoz, Maria Queralt Salas Gay, Maria Suarez-Lledo, Francesc Fernández-Avilés, Montserrat Rovira, Carlos Solano, Ariadna Perez-Martinez, Jose Piñana, Ana Belén Bocanegra, Joud Zanabili, Maite Zudaire, José Antonio Pérez-Simón

Blood (2025) 146 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2025-7760

Published: 2025

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Blood (2024) 144 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2024-203251

Published: 2024

Journal Articles

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Blood (2024) 144 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2024-207118

Published: 2024

Journal Articles

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Blood (2024) 144 (Supplement 1): 787.

https://doi.org/10.1182/blood-2024-204867

Published: 2024

Journal Articles

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Blood (2024) 144 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2024-205007

Published: 2024

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Usefulness of C5b9 deposition analysis for the diagnosis, treatment, and monitoring of patients with transplant-associated thrombotic microangiopathy

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Monocytosis as prognostic factor for chronic graft versus host disease

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only